Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the clinical features and bevacizumab efficacy for macular edema (ME) following branch retinal vein occlusion (BRVO) stratified by baseline visual acuity.

Methods

This retrospective study included a total 117 eyes from 117 consecutive patients with ME following BRVO, who received PRN intravitreal bevacizumab injection and were followed for more than 6 months. The eyes were categorized into three groups according to baseline best-corrected visual acuity (BCVA) (group A, BCVA <20/200; group B, BCVA ≥20/200 and ≤20/40; group C, BCVA >20/40). Baseline demographics, clinical features, BCVA, and central retinal thickness (CRT) at 1, 3, 6, and 12 months after injection and the number of injections were compared.

Results

Groups A–C included 11, 83, and 23 eyes, respectively. The mean baseline CRT was thickest in group A (810.1, 580.8, and 473.5 μm in groups A–C, respectively; p < 0.001) and the percentage of eyes with macular ischemia increased in the worst BCVA group (45.5, 25.0, and 4.3 % in groups A–C, respectively; p = 0.005). The mean BCVA and CRT improved at 1, 3, 6, and 12 months after treatment compared to baseline values in all groups (all, p < 0.001). The number of injections for 6 months was greater in the worst BCVA group (3.2, 2.3, and 1.9 injections in groups A–C, respectively; p = 0.009).

Conclusion

In ME following BRVO, baseline visual acuity correlates with macular ischemia and baseline CRT. Intravitreal bevacizumab treatment results in significant anatomical and functional improvement regardless of baseline visual acuity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247

    Article  CAS  PubMed  Google Scholar 

  2. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F (2011) Retinal vein occlusion: current treatment. Ophthalmologica 225:135–143

    Article  CAS  PubMed  Google Scholar 

  5. Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, Ota I, Miyake K, Terasaki H (2009) Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina 29:1242–1248

    Article  PubMed  Google Scholar 

  6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2004) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335

    Google Scholar 

  7. Figueroa MS, Contreras I, Noval S, Arruabarrena C (2010) Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 94:1052–1056

    Article  CAS  PubMed  Google Scholar 

  8. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606, e602

    Article  CAS  PubMed  Google Scholar 

  9. Rabena MD, Pieramici DJ, Castellarin AA, Ma’an AN, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425

    Article  PubMed  Google Scholar 

  10. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE (2009) Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina 29:913–925

    Article  PubMed  Google Scholar 

  11. Wu L, AREVALO JF, Berrocal MH, Maia M, Roca JA, Morales-Canton V, Alezzandrini AA, Diaz-Llopis MJ (2009) Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 29:1396–1403

    Article  PubMed  Google Scholar 

  12. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522

    Article  CAS  PubMed  Google Scholar 

  13. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH, Group RVOS (2011) Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249:183–192

    Article  CAS  PubMed  Google Scholar 

  14. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247

    Article  CAS  PubMed  Google Scholar 

  15. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Investigators B (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112, e1101

    Article  PubMed  Google Scholar 

  16. Thapa R, Maharjan N, Paudyal G (2012) Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results. Clin Ophthalmol (Auckland, NZ) 6:1057–1062

    Article  CAS  Google Scholar 

  17. Otani T, Kishi S, Maruyama Y (1999) Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 127:688–693

    Article  CAS  PubMed  Google Scholar 

  18. Lin LL, Dong YM, Zong Y, Zheng QS, Fu Y, Yuan YG, Huang X, Qian G, Gao QY (2016) Study of retinal vessel oxygen saturation in ischemic and non-ischemic branch retinal vein occlusion. Int J Ophthalmol 9:99–107

    PubMed  PubMed Central  Google Scholar 

  19. Parodi MB, Di Stefano G, Ravalico G (2008) Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 28:97–102

    Article  PubMed  Google Scholar 

  20. Rehak J, Dusek L, Chrapek O, Fric E, Rehak M (2011) Initial visual acuity is an important prognostic factor in patients with branch retinal vein occlusion. Ophthalmic Res 45:204–209

    Article  PubMed  Google Scholar 

  21. Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A (2012) Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. Jpn J Ophthalmol 56:159–164

    Article  CAS  PubMed  Google Scholar 

  22. Noma H, Funatsu H, Mimura T, Shimada K (2011) Influence of ischemia on visual function in patients with branch retinal vein occlusion and macular edema. Clin Ophthalmol (Auckland, NZ) 5:679–685

    Article  Google Scholar 

  23. Parodi MB, Visintin F, Della Rupe P, Ravalico G (1995) Foveal avascular zone in macular branch retinal vein occlusion. Int Ophthalmol 19:25–28

    Article  CAS  PubMed  Google Scholar 

  24. Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, Ogino K, Yoshimura N (2012) Relationship between perifoveal capillaries and pathomorphology in macular oedema associated with branch retinal vein occlusion. Eye 26:771–780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, Group SSI (2009) SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 116:504–512

    Article  PubMed  PubMed Central  Google Scholar 

  26. Siegel RA, Dreznik A, Mimouni K, Bor E, Weinberger D, Bourla DH (2012) Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting. Curr Eye Res 37:823–829

    Article  CAS  PubMed  Google Scholar 

  27. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27–33

    Article  CAS  PubMed  Google Scholar 

  28. Yamada R, Nishida A, Shimozono M, Kameda T, Miyamoto N, Mandai M, Kurimoto Y (2015) Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion. Jpn J Ophthalmol 59:389–393

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Yeungnam University College of Medicine, #170 Hyunchungro, Nam-gu, Daegu, 42415, Korea

    Mirae Kim, Seongyong Jeong & Min Sagong

Authors
  1. Mirae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seongyong Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min Sagong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Min Sagong.

Ethics declarations

Funding

Min Sagong provided financial support in the form of 2015 Yeungnam University research grant. The sponsor had no role in the design or conduct of this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, M., Jeong, S. & Sagong, M. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Graefes Arch Clin Exp Ophthalmol 255, 691–697 (2017). https://doi.org/10.1007/s00417-016-3535-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-016-3535-3

Keywords

Search

Navigation